Group 1 - Tianjin Tasly Pharmaceutical announced the convening of its 12th meeting of the 9th Board of Directors on August 14, 2025, to review the "2025 Semi-Annual Report" and other documents [1] - For the year 2024, the revenue composition of Tasly is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biological Drugs 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tasly's market capitalization is 24.2 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing uncertainty regarding an 11 billion yuan acquisition, as the major client of the acquisition target has been in debt crisis for two years, raising questions about its ability to contribute significant revenue [1]
天士力:8月14日召开董事会会议